Jane Street Group LLC Increases Position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)


Share on StockTwits

Jane Street Group LLC lifted its position in shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) by 360.1% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 80,560 shares of the biotechnology company’s stock after buying an additional 63,051 shares during the period. Jane Street Group LLC owned 0.21% of Aldeyra Therapeutics worth $553,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Avidity Partners Management LP raised its stake in Aldeyra Therapeutics by 0.3% during the fourth quarter. Avidity Partners Management LP now owns 1,435,000 shares of the biotechnology company’s stock worth $9,844,000 after purchasing an additional 5,000 shares during the period. BlackRock Inc. raised its stake in Aldeyra Therapeutics by 3.9% during the fourth quarter. BlackRock Inc. now owns 780,304 shares of the biotechnology company’s stock worth $5,352,000 after purchasing an additional 29,160 shares during the period. Point72 Asset Management L.P. purchased a new position in Aldeyra Therapeutics during the third quarter worth approximately $4,757,000. ExodusPoint Capital Management LP raised its stake in Aldeyra Therapeutics by 1,121.5% during the fourth quarter. ExodusPoint Capital Management LP now owns 139,520 shares of the biotechnology company’s stock worth $957,000 after purchasing an additional 128,098 shares during the period. Finally, California Public Employees Retirement System purchased a new position in Aldeyra Therapeutics during the third quarter worth approximately $488,000. 61.29% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have weighed in on the stock. HC Wainwright assumed coverage on shares of Aldeyra Therapeutics in a research note on Monday, February 8th. They set a “buy” rating and a $26.00 price target on the stock. SVB Leerink assumed coverage on shares of Aldeyra Therapeutics in a research note on Thursday, March 18th. They set an “outperform” rating and a $22.00 price target on the stock. Finally, Berenberg Bank began coverage on shares of Aldeyra Therapeutics in a research note on Wednesday, December 16th. They set a “buy” rating and a $32.00 price target on the stock. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $24.32.

In other news, major shareholder Perceptive Advisors Llc purchased 1,368,421 shares of the stock in a transaction that occurred on Tuesday, January 19th. The stock was acquired at an average cost of $9.50 per share, with a total value of $12,999,999.50. The acquisition was disclosed in a document filed with the SEC, which is available at this link. 15.00% of the stock is currently owned by company insiders.

Aldeyra Therapeutics stock opened at $12.35 on Thursday. Aldeyra Therapeutics, Inc has a 52-week low of $2.15 and a 52-week high of $14.62. The firm has a fifty day moving average of $11.97 and a 200-day moving average of $9.24. The firm has a market capitalization of $583.50 million, a P/E ratio of -9.57 and a beta of 1.86. The company has a quick ratio of 13.65, a current ratio of 13.65 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings results on Wednesday, March 10th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.02). On average, research analysts expect that Aldeyra Therapeutics, Inc will post -1.12 EPS for the current fiscal year.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A.

Recommended Story: What are economic reports?

Want to see what other hedge funds are holding ALDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aldeyra Therapeutics, Inc (NASDAQ:ALDX).

Institutional Ownership by Quarter for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.